NASDAQ:ALBO - Albireo Pharma Stock Price, Forecast & News

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Albireo Pharma Inc (NASDAQ:ALBO) posted its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.55) by $0.18. The biopharmaceutical company had revenue of $1.39 million for the quarter, compared to analyst estimates of $1.38 million. View Albireo Pharma's Earnings History.

Albireo Pharma is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Albireo Pharma.

4 analysts have issued 1-year price objectives for Albireo Pharma's stock. Their forecasts range from $39.00 to $69.00. On average, they anticipate Albireo Pharma's stock price to reach $56.67 in the next year. This suggests a possible upside of 129.0% from the stock's current price. View Analyst Price Targets for Albireo Pharma.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Albireo Pharma.

News coverage about ALBO stock has trended extremely negative recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Albireo Pharma earned a coverage optimism score of -5.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Albireo Pharma.

Albireo Pharma saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 688,900 shares, a decrease of 13.0% from the January 15th total of 791,600 shares. Based on an average daily trading volume, of 77,500 shares, the short-interest ratio is currently 8.9 days. Currently, 6.8% of the shares of the company are short sold. View Albireo Pharma's Current Options Chain.

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer LP Unit (ET), Heat Biologics (HTBX), CBL & Associates Properties (CBL), GW Pharmaceuticals PLC- (GWPH), Martin Midstream Partners (MMLP), Cornerstone Total Return Fund (CRF), Palatin Technologies (PTN), Exelixis (EXEL), Viking Therapeutics (VKTX) and SandRidge Permian Trust (PER).

Albireo Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include ArrowMark Colorado Holdings LLC (6.83%), Point72 Asset Management L.P. (1.67%), State Street Corp (1.53%), Chicago Capital LLC (1.38%), Victory Capital Management Inc. (1.20%) and Victory Capital Management Inc. (1.20%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford. View Institutional Ownership Trends for Albireo Pharma.

ALBO stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Heartland Advisors Inc., Victory Capital Management Inc., Victory Capital Management Inc., Goldman Sachs Group Inc., Blair William & Co. IL, State Street Corp and Bank of America Corp DE. Company insiders that have sold Albireo Pharma company stock in the last year include Patrick Taylor Horn and Simon NR Harford. View Insider Buying and Selling for Albireo Pharma.

ALBO stock was acquired by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Point72 Asset Management L.P., Bank of Montreal Can, California Public Employees Retirement System, MAI Capital Management, Alpine Global Management LLC, Birchview Capital LP and M&T Bank Corp. Company insiders that have bought Albireo Pharma stock in the last two years include Perceptive Advisors Llc and Ronald Harold Wilfred Cooper. View Insider Buying and Selling for Albireo Pharma.

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALBO stock can currently be purchased for approximately $24.74.